Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis (HIT)
Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis
Sponsor: Centre Francois Baclesse
A PHASE1/PHASE2 clinical study on Carcinomatous Meningitis and Metastatic Breast Cancer, this trial is completed. The trial is conducted by Centre Francois Baclesse and has accumulated 9 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Francois Baclesse
- Centre Leon Berard
- Centre Oscar Lambret
- Groupe Hospitalier Pitie-Salpetriere
- Hoffmann-La Roche
- Institut Bergonié
- Institut Curie
- Institut du Cancer de Montpellier - Val d'Aurelle
- University Hospital, Grenoble
- University Hospital, Toulouse
For direct contact, visit the study record on ClinicalTrials.gov .